Sign In
Buy LLY
$1,185.71
-7.09 (-0.594%)
At Close: Aug 07, 2026
3 Pharma Stocks to Sell in February Before They Crash and Burn
02:39pm, Friday, 02'nd Feb 2024
The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising
4 Large Drug Stocks Trying to Survive the Industry Challenges
09:51am, Friday, 02'nd Feb 2024
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin
Lilly (LLY) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Thursday, 01'st Feb 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart
Why Eli Lilly Stock Topped the Market Today
06:16pm, Wednesday, 31'st Jan 2024
A rival posted highly encouraging annual results for 2023. A great deal of its growth was due to a certain category of medications Eli Lilly also has in its product lineup.
Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
01:25pm, Wednesday, 31'st Jan 2024
I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030. GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects on
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
12:03pm, Wednesday, 31'st Jan 2024
There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Wednesday, 31'st Jan 2024
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club
06:46am, Wednesday, 31'st Jan 2024
Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.
Stocks: Reasons to go in on Eli Lilly stock, but avoid Tesla
05:04pm, Tuesday, 30'th Jan 2024
The S&P 500's (^GSPC) historic growth story over the past six months cannot and should not be missed by investors. Deciphering which stocks on the S&P 500 to pick for further growth can be daunting.
Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Tuesday, 30'th Jan 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
06:46pm, Monday, 29'th Jan 2024
Eli Lilly (LLY) concluded the recent trading session at $645, signifying a +0.9% move from its prior day's close.
Eli Lilly in ‘good dialogue' with Germany on weight-loss drug coverage
11:25am, Monday, 29'th Jan 2024
Eli Lilly & Co (NYSE: LLY) is in the green this morning following a report that it's in talks with Germany to have its weight-loss drug be included in the country's public health coverage.
Better Buy in 2024: The "Magnificent Seven" or the "Terrific 10"?
06:26am, Monday, 29'th Jan 2024
There's lucrative growth in the healthcare segment. The largest financial companies are no longer big banks.
Could Eli Lilly Be a Trillion-Dollar Company by 2030?
08:25am, Saturday, 27'th Jan 2024
Eli Lilly's valuation has soared over the last year given the blockbuster success of treatments such as Mounjaro and Verzenio. The company has other opportunities, including plaque psoriasis and psori
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
03:57pm, Friday, 26'th Jan 2024
After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.
